NCT03072407View on ClinicalTrials.gov

MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

November 24, 2015

Primary Completion Date

November 2, 2016

Study Completion Date

November 15, 2016

Conditions
Type2 Diabetes Mellitus
Interventions
BIOLOGICAL

PB-119 injection

BIOLOGICAL

PB-119 injection placebo

Trial Locations (2)

33014

Clinical Pharmacology of Miami, Inc., Miami

07601

Frontage Clinical Services. Inc., Hackensack

All Listed Sponsors
lead

PegBio Co., Ltd.

OTHER

NCT03072407 - MAD Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PB-119 to Subjects With T2DM | Biotech Hunter | Biotech Hunter